41st Annual Miami Breast Cancer Conference® - Abstracts

home / journals / mbcc-suppl / 41st-annual-miami-breast-cancer-conference---abstracts
1 Centrally Located Breast Cancer Is More Aggressive in Bahraini Patients

1 Centrally Located Breast Cancer Is More Aggressive in Bahraini Patients

Hamdi Al Shenawil;Rami Yaghan;Noor Al Shenawi;Amer Almarabheh;Lamees Yaghan;Fatima Al Shenawi;Suhair Al Saad
September 2nd 2024
ArticleMedical Oncology
2 Is Laterality in Breast Cancer Still Worth Studying? Local Experience in Bahrain

2 Is Laterality in Breast Cancer Still Worth Studying? Local Experience in Bahrain

Suhair Al Saad;Hamdi Al Shenawil;Amer Almarabheh;Noor Al Shenawi;Abdulla Ismaeel Mohamed;Rami Yaghan
August 30th 2024
ArticleMedical Oncology
3 Gender Disparities in the National Institutes of Health Funding for Breast Cancer

3 Gender Disparities in the National Institutes of Health Funding for Breast Cancer

Muhammad Zain Farooq;Aruba Sohail;Sara Khan;Ibrahim Zahid;Shaival Thakore;Janta Ukrani;Michael Vishal Jaglal
August 30th 2024
ArticleMedical Oncology
4 Bacopaside: Exploring Its Potential in Addressing Chemoresistance and Modulating Doxorubicin Accumulation in Triple-Negative Breast Cancer Cells

4 Bacopaside: Exploring Its Potential in Addressing Chemoresistance and Modulating Doxorubicin Accumulation in Triple-Negative Breast Cancer Cells

Sima K. Rad;Kenny K. L. Yeo;Runhao Li;Saifei Liu;Fangmeinuo Wu;Kevin A. Fenix;Timothy J. Price;Wendy Ingman;Amanda R. Townsend;Eric Smith
August 29th 2024
ArticleMedical Oncology
5 Predictors of Axillary Complete Pathologic Response in Hormone Receptor–Positive, HER2-Negative, Clinically Node-Positive Breast Cancer

5 Predictors of Axillary Complete Pathologic Response in Hormone Receptor–Positive, HER2-Negative, Clinically Node-Positive Breast Cancer

Anshumi Desai;Youley Tjendra;Eli Avisar
August 29th 2024
ArticleMedical Oncology
6 Treatment Outcomes of the KEYNOTE-522 Regimen in an Ethnically Diverse Patient Population

6 Treatment Outcomes of the KEYNOTE-522 Regimen in an Ethnically Diverse Patient Population

Mukuhi Ng’ang’a;Susan Burdette-Radoux, MD;Abhigna Kodali;Gene Sobol;Michael Silver;Charusheela Andaz;Patrick I. Borgen, MD;Joshua Feinberg
August 27th 2024
ArticleMedical Oncology
7 Real-World Efficacy and Adverse Events of Neoadjuvant Immunotherapy in Early-Stage Triple-Negative Breast Cancer Patients: A Multicenter Experience

7 Real-World Efficacy and Adverse Events of Neoadjuvant Immunotherapy in Early-Stage Triple-Negative Breast Cancer Patients: A Multicenter Experience

Archit Patel;Arya Mariam Roy;Malak Alharbi;Nicole Held;Anumita Chakraborty;Kayla Catalfamo;Kristopher Attwood;Lubna N. Chaudhary;Saba S. Shaikh;Shipra Gandhi
August 27th 2024
ArticleMedical Oncology
8 Using a Liquid Biopsy Mediated Approach for Determination of HER2 Amplification Status in Patient Samples

8 Using a Liquid Biopsy Mediated Approach for Determination of HER2 Amplification Status in Patient Samples

Xiaojie Zhang;Janet C. Dickerson;Stephenie Jones;Judy Muller-Cohn;Yipeng Wang;Rolf Muller;Kay Yeung
August 25th 2024
ArticleMedical Oncology
9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

Aditya Bardia, MD, MPH;Joyce O’Shaughnessy, MD;Francois Clement Bidard;Phillipe Aftimos;Javier Cortes;Janice Lu, MD, PhD ;Giulia Tonini;Kathy Puyana Theall;Alessandro Paoli;Virginia Kaklamani, MD, DSc
August 24th 2024
ArticleMedical Oncology
10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

Adam M. Brufsky, MD, PhD;Xianchen Liu;Benjamin Li;Lynn McRoy;Connie Chen;Doris Makari;Rachel M. Layman;Hope S. Rugo, MD
August 20th 2024
ArticleMedical Oncology
11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756

11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756

Fatima Cardoso;Joyce O’Shaughnessy, MD;Heather McArthur, MD, MPH;Peter Schmid, MD;Javier Cortés, MD;Nadia Harbeck, MD, PhD;Melinda L. Telli, MD;David W. Cescon;Peter A. Fasching;Zhimin Shao;Delphine Loirat;Yeon Hee Park;Manuel Gonzalez Fernandez;Gábor Rubovszky;Seock-Ah Im;Rina Hui;Toshimi Takano;Fabrice André;Hiroyuki Yasojima;Zhenzhen Liu;Yu Ding;Liyi Jia;Vassiliki Karantza;Konstantinos Tryfonidis;Aditya Bardia, MD, MPH
August 18th 2024
ArticleMedical Oncology
12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

Javier Cortés, MD;François-Clément Bidard;Aditya Bardia, MD, MPH;Virginia G. Kaklamani, MD, DSc;Ioanna Vlachaki;Giulia Tonini;Nassir Habboubi;Philippe Aftimos
August 17th 2024
ArticleMedical Oncology
13 The Cause and Eradication of Breast Cancer

13 The Cause and Eradication of Breast Cancer

Paul Dantzig
August 16th 2024
ArticleMedical Oncology
14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

Nagi El Saghir;Yoon Sim Yap;Yesim Eralp;Seock-Ah Im;Hamdy Abdel Azim;Julie Rihani;Nikita Volkov;Shin-Cheh Chen;Hakan Harputluoglu;Patrapim Sunpaweravong;Yuan-Ching Chang;Teresa Delgar Alfaro;Jiwen Wu;Huilin Hu;Melissa Gao;Yen-Shen Lu
August 15th 2024
ArticleMedical Oncology
15 Concurrent Use of Abemaciclib and Radiation Therapy (RT) Among Patients With HR+, HER2– Metastatic Breast Cancer (MBC): Real-World Utilization and Safety

15 Concurrent Use of Abemaciclib and Radiation Therapy (RT) Among Patients With HR+, HER2– Metastatic Breast Cancer (MBC): Real-World Utilization and Safety

Wambui Gathirua-Mwangi;Sangmi Kim;Holly Martin;Tasneem Lokhandwala;Shen Zheng;Eileen Farrelly;Sarah Rybowski
August 13th 2024
ArticleMedical Oncology
16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

Matthew P. Goetz, MD;Seth A. Wander;Thomas Bachelot;Gerald Batist;Javier Cortés, MD;Massimo Cristofanilli, MD;Giuseppe Curigliano;Alexandre de Nonneville;Einav Nili Gal-Yam;Komal Jhaveri;Cynthia X. Ma, MD, PhD;Heather A. Parsons, MD, MPH;Hope S. Rugo, MD;Sarah L. Sammons;Daniel G. Stover;Chris Twelves, MD, FRCP;Aditya Bardia, MD, MPH;Paul V. Plourde;David J. Portman;Senthil Damodaran
August 12th 2024
ArticleMedical Oncology
17 TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Chemotherapy (CT) Plus Pembrolizumab in Patients (pts) With PD-L1–Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC)

17 TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Chemotherapy (CT) Plus Pembrolizumab in Patients (pts) With PD-L1–Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC)

Stephanie L. Graff, MD;Peter Schmid, MD;Massimo Cristofanilli, MD;David W. Cescon;Tina Hovey;Karson Tse;Petra Vuković;Joyce O’Shaughnessy, MD
August 11th 2024
ArticleMedical Oncology
18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

Erika P. Hamilton, MD;Rinath M. Jeselsohn;Sara A. Hurvitz, MD;Dejan Juric;Hyo S Han;Melinda L. Telli, MD;George Zahrah;Rita Nanda, MD;Yuanyuan Zhang;Weiwei Tan;Elizabeth Duperret;Eric Zhi;Cecile Mather;Anne F. Schott, MD
August 10th 2024
ArticleMedical Oncology
19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

Lowell Hart;Seock-Ah Im;Sara M. Tolaney, MD, MPH;Mario Campone;Timothy Pluard;Berta Sousa;Gilles Freyer;Thomas Decker;Kevin Kalinsky, MD, MS;Astrid Thuerigen;Melissa Gao;Huilin Hu;Sherko Kümmel
August 9th 2024
ArticleMedical Oncology
20 Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

20 Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

Sara M. Tolaney, MD, MPH;Aditya Bardia, MD, MPH;Frederik Marmé;Javier Cortés, MD;Peter Schmid, MD;Delphine Loirat;Olivier Trédan;Eva Ciruelos;Florence Dalenc;Patricia Gómez Pardo;Komal L. Jhaveri;Rosemary Delaney;Theresa Valdez;Oh Kyu Yoon;Hao Wang;Wendy Verret;Hope S. Rugo, MD
August 8th 2024
ArticleMedical Oncology
21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial

21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial

Gabriel N. Hortobagyi, MD, FACP;Daniil Stroyakovskiy;Denise A. Yardley, MD;Chiun-Sheng Huang;Peter A. Fasching;John Crown;Aditya Bardia, MD, MPH;Stephen Chia;Seock-Ah Im;Miguel Martin, MD, PhD;Sherene Loi, MD, PhD;Binghe Xu;Sara A. Hurvitz, MD;Carlos Barrios;Michael Untch, MD, PhD;Rebecca Moroose;Frances Visco;Federico Parnizari;Farhat Ghaznawi;Zheng Li;Sorcha Waters;Arunava Chakravartty;Dennis J. Slamon, MD, PhD
August 7th 2024
ArticleMedical Oncology
22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

Sara A. Hurvitz, MD;Anne F. Schott, MD;Cynthia X. Ma, MD, PhD;Rita Nanda, MD;George Zahrah;Natasha Hunter, MD;Antoinette R. Tan;Melinda L. Telli, MD;Jesus Anampa Mesias;Rinath M. Jeselsohn;Pamela N. Munster, MD;Eric Zhi;Elizabeth Duperret;Cecile Mather;Erika P. Hamilton, MD;Hyo S Han
August 4th 2024
ArticleMedical Oncology
23 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2-Negative (HER2) Breast Cancer (BC)

23 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2-Negative (HER2) Breast Cancer (BC)

Nuhad Ibrahim, MD;Sung-Bae Kim;Nancy U. Lin, MD;Ahmad Awada;Eva Ciruelos Gil;Alessandro Di Sanzo;Bartomeu Piza Vallespir;Kathy Puyana Theall;Erika P. Hamilton, MD
August 3rd 2024
ArticleMedical Oncology
24 Patient Preferences for CDK4/6 Inhibitor Treatments in HR+/HER2– Early Breast Cancer: A Discrete Choice Survey Study

24 Patient Preferences for CDK4/6 Inhibitor Treatments in HR+/HER2– Early Breast Cancer: A Discrete Choice Survey Study

Erica L. Mayer, MD, MPH;Mary Lou Smith;Annie Guérin;Dominick Latrémouille-Viau;Nisha C. Hazra;Yan Meng;Wendi Qu;Remi Bellefleur;Vaidyanathan Ganapathy;Liz Santarsiero;Robert Morlock;Maryam Lustberg
August 2nd 2024
ArticleMedical Oncology
25 Treatment Patterns and Clinical Outcomes Following Endocrine Resistance Among HER2-Low Metastatic Breast Cancer Patients— Retrospective Observational Study

25 Treatment Patterns and Clinical Outcomes Following Endocrine Resistance Among HER2-Low Metastatic Breast Cancer Patients— Retrospective Observational Study

Sandhya Mehta;Kristin M. Zimmerman Savill;Peng Wang;Prathamesh Pathak;Clara Lam;Jackie Kwong;Bruce Feinberg
July 28th 2024
ArticleMedical Oncology
26 Prediction of Chemotherapy Benefit by MammaPrint® in Patients With HR+HER2- Early-Stage Breast Cancer From Real-World Evidence Studies

26 Prediction of Chemotherapy Benefit by MammaPrint® in Patients With HR+HER2- Early-Stage Breast Cancer From Real-World Evidence Studies

William Audeh, MD;Harshini Ramaswamy;Andrea Menicucci
July 27th 2024
ArticleMedical Oncology
27 CARDIAC-STAR: Prevalence of Cardiovascular (CV) Comorbidities in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

27 CARDIAC-STAR: Prevalence of Cardiovascular (CV) Comorbidities in Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

Heather Moore;Avirup Guha;Doris Makari;Rachael McCaleb;Irene Arias;Stella Stergiopoulos;Benjamin Li;Michael Fradley;Susan Dent, MD
July 25th 2024
ArticleMedical Oncology
28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

Gabrielle Rocque;Joanne L. Blum, MD, PhD;Yan Ji;Eric Gauthier;Yao Wang;Monica Z. Montelongo;Joseph C. Cappelleri;Connie Chen;Meghan S. Karuturi;Debu Tripathy, MD
July 24th 2024
ArticleMedical Oncology
29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Erika P. Hamilton, MD;Sara A. Hurvitz, MD;Sara M. Tolaney, MD, MPH;Virginia Kaklamani, MD, DSc;Paula Muñoz Romero;Shannon Matheny;Kathy Puyana Theall;Joyce A. O’Shaughnessy
July 21st 2024
ArticleMedical Oncology
30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri;Seock-Ah Im;Senia Pernas;Michelino De Laurentiis;Shusen Wang;Noelia Martínez Jañez;Giuliano Borges;David W. Cescon;Masaya Hattori;Yen-Shen Lu;Erika P. Hamilton, MD;Qingyuan Zhang;Junji Tsurutani;Kevin Kalinsky, MD, MS;Lu Xu;Neelima Denduluri;Binghe Xu;Barbara Pistilli
July 20th 2024
ArticleMedical Oncology
123>